GL-ONC1
products : gl-onc1
Preclinical Tumor Therapy
Preclinical animal studies at the Company’s laboratories and at those of its research collaborators, GL-ONC-1 have established a compelling preclinical profile. In animal models, tumor stabilization and/or elimination was observed in more than 25 different human cancers, including:
- Pancreatic Cancer
- Mesothelioma
- Breast Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer
- Kidney Cancer
- Bone Cancer (Osteosarcoma)
- Head & Neck Cancer (Squamous Cell carcinoma and Thyroid carcinoma)
- Melanoma
- Colon Cancer
- Cervical Cancer
- Renal-Cell Carcinoma
- Pediatric Cancers
- Medulloblastoma
- Wilm’s Tumor
- Rhabdoid Tumor
- Rhabdomyosarcoma
GL-ONC1 has shown that it can safely colonize and replicate selectively in cell lines in-vitro and in solid human tumors in nude mice across multiple cancer types and cancer cell lines. While GL-ONC1 has not yet been evaluated in hematological cancers, it is possible that GL-ONC1 could have therapeutic effects in both solid and non-solid tumors.